Stage IV Melanoma
110
0
5
63
Key Insights
Highlights
Success Rate
69% trial completion
Published Results
35 trials with published results (32%)
Research Maturity
63 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
25.5%
28 terminated out of 110 trials
69.2%
-17.3% vs benchmark
2%
2 trials in Phase 3/4
56%
35 of 63 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 63 completed trials
Clinical Trials (110)
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Investigating Participation Patterns Among Stage IV Melanoma Patients
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery